Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bilibili Inc (BILI) vs Pfizer Inc (PFE) Price & Performance

Bilibili IncTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Bilibili Inc vs Pfizer Inc — how do they compare? Bilibili Inc trades at $17.75 (market cap $7.65B), while Pfizer Inc trades at $26.56 (market cap $151.73B). The key difference: Pfizer Inc is far larger — about 19.8× Bilibili Inc's market cap, and Pfizer Inc pays a 6.46% dividend while Bilibili Inc pays none. Which is the better fit depends on your goals.

BILIPFE
Market Cap
$7.65B$151.73B
Sector
MediaHealth
52-Week High
$35.92$28.56
52-Week Low
$15.96$23.60
Enterprise Value
$5.49B$203.22B
Volume
29,869,932
Dividend Yield
6.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bilibili Inc

Bilibili (BILI) trades at $18.74, up 0.48% with neutral technical signals. The company reported strong Q1 2026 earnings of $0.19 per share, beating estimates, and maintains solid profitability with a 4.58% net margin. Recent news highlights a new $300 million share repurchase program and upcoming Q2 2026 results on August 27, 2026. Technical indicators show mixed signals with RSI neutral but moving averages bullish.

Bilibili presents a compelling investment case with consistent earnings beats and strong analyst support (83% buy ratings). However, risks include competitive pressures in China's video platform market and reliance on advertising revenue growth. The upcoming Q2 earnings report will be crucial for validating the company's monetization strategy and user engagement metrics.

Pfizer Inc

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bilibili Inc

Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.

Read more on BILI

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE